**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 42877

**Manuscript Type:** CASE REPORT

**Sarcomatoid carcinoma of the pancreas: A case report**

Zhou DK *et al.* Sarcomatoid carcinoma of the pancreas

Dong-Kai Zhou, Bing-Qiang Gao, Wang Zhang, Xiao-Hui Qian, Li-Xiong Ying, Wei-Lin Wang

**Dong-Kai Zhou, Bing-Qiang Gao, Wang Zhang, Xiao-Hui Qian, Wei-Lin Wang,** Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**Dong-Kai Zhou, Bing-Qiang Gao, Wang Zhang, Xiao-Hui Qian, Wei-Lin Wang,** Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**Li-Xiong Ying,** Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**Wei-Lin Wang**, Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**Wei-Lin Wang,** State Key Laboratory and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**ORCID number:** Dong-Kai Zhou (0000-0003-0705-9796); Bing-Qiang Gao (0000-0002-1265-0217); Wang Zhang (0000-0002-0683-6007); Xiao-Hui Qian (0000-0002-3294-1337); Li-Xiong Ying (0000-0001-9957-5178); Wei-Lin Wang (0000-0001-9432-2649).

**Author contributions:** Zhou DK collected case data and prepared the photos; Zhou DK and Gao BQ wrote the manuscript; Ying LX proofread the pathologic materials; Zhang W, Qian XH, and Wang WL proofread and revised the manuscript; all of the authors approved the final version to be published.

**Supported by** National Natural Science Foundation of China, No. 81572307 and No. 81773096; Major Project of Medical and Health Technology Development Program in Zhejiang Province, No. 7211902; and Science and Technology Major Project of Zhejiang Province, No. 2014C13G2010059 and No. 2014C03041-2.

**Informed consent statement:** Informed consent was obtained from the patient.

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest related to this report.

**CARE Checklist (2016) statement:** Guidelines of the CARE Checklist (2016) have been adopted while writing this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author to:** **Wei-Lin Wang, MD, PhD,** **Doctor,** Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. wam@zju.edu.cn

**Telephone:** +86-571-87236601

**Fax:** +86-571-87236617

**Received:** October 16, 2018

**Peer-review started:** October 16, 2018

**First decision:** November 22, 2018

**Revised:** December 4, 2018

**Accepted:** December 7, 2018

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Sarcomatoid carcinoma of the pancreas (SCP) is a rare and aggressive epithelial tumor that has both epithelial and mesenchymal features. It is characterized by sarcomatous elements with evidence of epithelial differentiation. And the term “sarcomatoid carcinoma” is often confused with “carcinosarcomas”.

***CASE SUMMARY***

We present a case of SCP with lymph node metastasis in a 59-year-old male patient. He had experienced darkening of the urine, scleral icterus, and fatigue for 4 weeks. Computed tomography and magnetic resonance imaging revealed a mass in the pancreatic head, and laboratory tests revealed elevated serum bilirubin levels. The patient underwent pancreaticoduodenectomy after biliary decompression. Histologically, spindle cells with marked nuclear atypia and brisk mitotic activity arranged in a storiform or fascicular pattern were present in the bulk of the tumor. Immunohistochemical analysis found that the spindle cells exhibited strong diffuse positivity for epithelial markers, indicative of epithelial differentiation. Accordingly, the pathologic diagnosis of the pancreatic neoplasm was SCP.

***CONCLUSION***

Although sarcomatoid carcinomas and carcinosarcomas have different pathologic features, both have epithelial origin.

**Key words:** Pancreas; Sarcomatoid carcinoma; Carcinosarcomas; Undifferentiated carcinomas; Spindle cell; Case report

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip****:** Sarcomatoid carcinoma of the pancreas is a rare and aggressive epithelial tumor with a sarcoma-like element. The term “sarcomatoid carcinoma” is often confused with “carcinosarcomas”. In the present study, we report a case of sarcomatoid carcinoma arising in the pancreas and discuss the similarities and differences between sarcomatoid carcinomas and carcinosarcomas.

Zhou DK, Gao BQ, Zhang W, Qian XH, Ying LX, Wang WL. Sarcomatoid carcinoma of the pancreas: A case report. *World J Clin Cases* 2018; In press

**INTRODUCTION**

Sarcomatoid carcinoma of the pancreas (SCP) is a rare and aggressive epithelial tumor with a sarcoma-like element, which exhibits epithelial markers and epithelial ultrastructural features. This could be considered as a stable intermediate stage of the epithelial–mesenchymal transition (EMT)[1,2]. As a variant of conventional pancreatic carcinoma, it has similar clinical features but shows a worse prognosis, with an average survival after diagnosis of 5 mo[3]. According to the World Health Organization (WHO) histological classification, it is grouped as an undifferentiated (anaplastic) carcinoma of the pancreas, together with anaplastic giant cell carcinoma and carcinosarcoma[3]. However, the terms “sarcomatoid carcinoma” and “carcinosarcoma” have been used interchangeably, and their definitions vary among authors. Herein, we report a case of sarcomatoid carcinoma arising in the pancreas and discuss the similarities and differences between sarcomatoid carcinomas and carcinosarcomas.

**CASE PRESENTATION**

***Chief complaints***

A 59-year-old male patient had experienced darkening of the urine, scleral icterus, and fatigue for 4 wk.

***History of present illness***

Biliary decompression by placing stents *via* endoscopic retrograde cholangiopancreatography had been performed at a different hospital a few days prior, because of elevated serum bilirubin levels and an ampullary tumor revealed by computed tomography (CT). The patient was admitted to our hospital for further evaluation and treatment.

***History of past illness***

He was a smoker but not a drinker of alcohol.

***Personal and family history***

His medical history and family history were unremarkable, with no diabetes or chronic pancreatitis.

***Physical examination***

A physical examination revealed scleral icterus, cutaneous jaundice and no palpable abdominal mass.

***Laboratory examinations***

Laboratory tests yielded the following results: total bilirubin 44 μmol/L (reference < 21 μmol/L), direct bilirubin 31 μmol/L (reference < 5 μmol/L), alanine aminotransferase 97 U/L (reference < 40 U/L), and carbohydrate antigen 19-914.6 U/L (reference < 37 U/L).

***Imaging examinations***

Contrast-enhanced CT revealed a low-density round mass measuring about 1.5 cm × 1.1 cm in the pancreatic head, which was slightly enhanced after intravenous administration of contrast material (Figure 1A). The pancreatic duct, extrahepatic bile duct, and intrahepatic ducts upstream of the obstruction were dilated (Figure 1B). Magnetic resonance imaging revealed an irregular bulky region in the head of the pancreas and a sheet-like lesion in the main pancreatic duct, with an iso-T1 and a long T2 signal.

**TREATMENT**

After his bilirubin levels returned to normal range, the patient underwent a laparotomy due to a suspected pancreatic tumor. During surgery, a firm tumor was palpated in the head of the pancreas. No direct invasion of the surrounding pancreatic tissue or adjacent organs, including the duodenum, stomach, liver, and peritoneum, was found. Subsequently, a pancreaticoduodenectomy was performed and regional lymph nodes were removed.

**FINAL DIAGNOSIS**

The gross pathology revealed a mass (2.5 cm × 2.5 cm × 2.0 cm) located mainly in the pancreatic head with extension into the main pancreatic duct. Microscopically, spindle cells with marked nuclear atypia and brisk mitotic activity arranged in a storiform or fascicular pattern were present in the bulk of the tumor (Figure 2A). The resection margins of the bile duct, stomach, and duodenum were free of tumor cells, but 3 of the 23 lymph nodes were positive for metastasis. An immunohistochemical examination was performed to identify the sarcomatous elements. The tumor did not express cluster of differentiation (CD) 34, CD117, soluble protein-100, smooth muscle actin, human melanoma black 45, and anaplastic lymphoma kinase, but exhibited strong diffuse positivity for cytokeratin 19 (Figure 2B) and vimentin (Figure 2C). More than 50% of the malignant cells expressed Ki-67. The metastatic lymph nodes exhibited similar histological and immunohistochemical results (Figure 3). Accordingly, the pathologic diagnosis of the pancreatic neoplasm was SCP with TNM stage IIB (T2N1M0).

**OUTCOME AND FOLLOW-UP**

The patient was discharged from the hospital on the eleventh postoperative day and died of liver metastasis and peritoneal metastasis 6 mo later.

**DISCUSSION**

Sarcomatoid carcinomas and carcinosarcomas are rare aggressive malignancies that can develop at various sites of the body, including genitourinary tract, respiratory tract, digestive tract, breast and thyroid glands, among others[1,4]. So far, 23 cases of sarcomatoid carcinomas or carcinosarcomas arising in the pancreas have been reported[5]. The use of the terms “sarcomatoid carcinoma” and “carcinosarcoma” is unclear and inconsistent both within and across organs, causing confusion for both pathologists and clinicians. For example, according to the WHO histological classification, carcinosarcoma is a hyponym of sarcomatoid carcinoma in lung tumors[6], while they, together with anaplastic giant cell carcinoma, are grouped as undifferentiated (anaplastic) carcinomas of the pancreas[3]. Anaplastic giant cell carcinoma is a relatively common type composed of pleomorphic mononuclear cells and bizarre-appearing giant cells[3], and the latter can be further divided into pleomorphic giant cells and osteoclast-like giant cells[7]. The definitions of pancreatic sarcomatoid carcinoma and carcinosarcoma vary among authors. Based on the histological, ultrastructural, and immunohistochemical evidence, it is undisputable that both sarcomatoid carcinoma and carcinosarcoma of the pancreas have epithelial and mesenchymal features.

Sarcomatoid carcinomas can exhibit a monophasic or biphasic appearance. The monophasic pattern, often referred to as spindle cell carcinoma, is akin to a soft tissue sarcoma without epithelioid areas. The biphasic pattern, the more frequent type, features a mixture of mesenchymal-like and epithelial-like cells with a transition zone[8]. The sarcomatous tissue of both biphasic and monophasic tumors shows evidence of epithelial differentiation, such as epithelial markers and epithelial ultrastructural features, rather than a specific line of mesenchymal differentiation[8,9]. SCP appear to be tumors at a stable intermediate stage of the EMT, as they retain many epithelial characteristics but have a mesenchymal morphology[1,2]. Transforming growth factor-β1 may induce the EMT in pancreas cells and promote the formation of SCP[10].

Carcinosarcomas are considered to be truly biphasic neoplasms composed of intermingled carcinomatous and sarcomatous components, which have epithelial and mesenchymal differentiation, respectively, according to their pathomorphological and immunohistochemical features[1]. These two components are typically separated without a transition zone[11]. The carcinomatous component expresses epithelial markers and exists as a variety of pathologic types; *e*.*g*., pancreatic ductal adenocarcinoma, mucinous cystadenocarcinoma, and intraductal papillary mucinous neoplasm. The sarcomatous component is sub-classified into homologous tissues (mostly malignant spindle cell proliferations) and heterologous tissues (such as osteosarcoma and rhabdomyosarcoma)[1]. The heterologous tissues are defined as those not native to the primary tumor site and show specific mesenchymal differentiation[12]. On immunohistochemical analysis, the sarcomatous components are positive for mesenchymal markers and negative for epithelial markers, indicative of mesenchymal differentiation. The classification of cases with weak or focal positivity for cytokeratin is controversial, and most researchers classify them as carcinosarcomas rather than sarcomatoid carcinomas[1,13,14]. While there is substantial evidence that both carcinosarcomas and sarcomatoid carcinomas have epithelial origin, carcinosarcomas show a more complete EMT of the sarcomatoid component compared to SCP[1].

As variants of conventional pancreatic carcinoma, sarcomatoid carcinoma and carcinosarcoma of the pancreas share similar clinical features. They are found more frequently in the head of the pancreas, and can infiltrate adjacent tissue including the duodenum, stomach, and peripheral nerves. Regional lymph node metastasis and distant metastasis can also occur. The tumors are predominantly found in older persons, and strike both genders with a similar frequency[3,5]. The presenting signs and symptoms include abdominal pain, jaundice, nausea/vomiting, and weight loss[1]. The recommended treatments for sarcomatoid carcinoma and carcinosarcoma mirror those of conventional pancreatic carcinoma[1,15]. Almost all patients undergo surgical treatment, the standard of which is pancreaticoduodenectomy. If needed, postoperative adjuvant chemotherapy with gemcitabine can be applied[1]. Although the tumor is related with the EMT, agents that block or reverse the EMT are at a very early stage of development[15]. Irrespective of the treatment provided, patients have an extremely poor prognosis, with an average survival after diagnosis of 5 mo[3]. According to a report by Shi *et al*[16], the median OS for T2N1M0 pancreatic ductal adenocarcinoma was 19 mo. In our case, by contrast, the patient survived 6 mo after surgery.

**CONCLUSION**

In summary, we present a case of pancreatic sarcomatoid carcinoma and describe its histologic and immunohistochemical features. Although sarcomatoid carcinomas and carcinosarcomas have different pathologic features, both can be interpreted as more malignant variants of conventional pancreatic carcinoma at different stages of the EMT. Therefore, the terms “sarcomatoid carcinoma” and “carcinosarcoma” can be used interchangeably for practical diagnostic purposes.

**REFERENCES**

1 **Ruess DA**, Kayser C, Neubauer J, Fichtner-Feigl S, Hopt UT, Wittel UA. Carcinosarcoma of the Pancreas: Case Report With Comprehensive Literature Review. *Pancreas* 2017; **46**: 1225-1233 [PMID: 28902796 DOI: 10.1097/MPA.0000000000000904]

2 **Lu BC**, Wang C, Yu JH, Shen ZH, Yang JH. A huge adenosquamous carcinoma of the pancreas with sarcomatoid change: an unusual case report. *World J Gastroenterol* 2014; **20**: 16381-16386 [PMID: 25473201 DOI: 10.3748/wjg.v20.i43.16381]

3 **Fukushima N,** Hruban RH, Kato Y, Klimstra DS, Klöppel G, Shimizu M, Terris B. Ductal adenocarcinoma variants and mixed neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010: 294-295

4 **Rakul NK,** Roshni S, Attokaran LL, Rari PM. Sarcomatoid carcinoma of pancreas with liver metastases – A case report with review of literature. *J Med Therap* 2017; **1**: 1-3 [DOI: 10.15761/JMT.1000112]

5 **Xie Y**, Xiang Y, Zhang D, Yao X, Sheng J, Yang Y, Zhang X. Sarcomatoid carcinoma of the pancreas: A case report and review of the literature. *Mol Med Rep* 2018; **18**: 4716-4724 [PMID: 30221744 DOI: 10.3892/mmr.2018.9489]

6 **Travis WD**, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *J Thorac Oncol* 2015; **10**: 1243-1260 [PMID: 26291008 DOI: 10.1097/JTO.0000000000000630]

7 **Layfield LJ**, Bentz J. Giant-cell containing neoplasms of the pancreas: an aspiration cytology study. *Diagn Cytopathol* 2008; **36**: 238-244 [PMID: 18335561 DOI: 10.1002/dc.20785]

8 **Guarino M**, Tricomi P, Giordano F, Cristofori E. Sarcomatoid carcinomas: pathological and histopathogenetic considerations. *Pathology* 1996; **28**: 298-305 [PMID: 9007945 DOI: 10.1080/00313029600169224]

9 **Kane JR**, Laskin WB, Matkowskyj KA, Villa C, Yeldandi AV. Sarcomatoid (spindle cell) carcinoma of the pancreas: A case report and review of the literature. *Oncol Lett* 2014; **7**: 245-249 [PMID: 24348857 DOI: 10.3892/ol.2013.1683]

10 **Ren CL**, Jin P, Han CX, Xiao Q, Wang DR, Shi L, Wang DX, Chen H. Unusual early-stage pancreatic sarcomatoid carcinoma. *World J Gastroenterol* 2013; **19**: 7820-7824 [PMID: 24282372 DOI: 10.3748/wjg.v19.i43.7820]

11 **Shi HY**, Xie J, Miao F. Pancreatic carcinosarcoma: first literature report on computed tomography imaging. *World J Gastroenterol* 2015; **21**: 1357-1361 [PMID: 25632213 DOI: 10.3748/wjg.v21.i4.1357]

12 **Giordano G**, Berretta R, Silini E. Primary pure spindle cell carcinoma (sarcomatoid carcinoma) of the ovary: A case report with immunohistochemical study. *Diagn Pathol* 2016; **11**: 70 [PMID: 27491291 DOI: 10.1186/s13000-016-0521-3]

13 **Darvishian F**, Sullivan J, Teichberg S, Basham K. Carcinosarcoma of the pancreas: a case report and review of the literature. *Arch Pathol Lab Med* 2002; **126**: 1114-1117 [PMID: 12204065 DOI: 10.1043/0003-9985(2002)1262.0.CO;2]

14 **Nakano T**, Sonobe H, Usui T, Yamanaka K, Ishizuka T, Nishimura E, Hanazaki K. Immunohistochemistry and K-ras sequence of pancreatic carcinosarcoma. *Pathol Int* 2008; **58**: 672-677 [PMID: 18801090 DOI: 10.1111/j.1440-1827.2008.02289.x]

15 **Pang A**, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. *J Clin Oncol* 2018; **36**: 210-216 [PMID: 29220296 DOI: 10.1200/JCO.2017.74.9523]

16 **Shi S**, Hua J, Liang C, Meng Q, Liang D, Xu J, Ni Q, Yu X. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. *Ann Surg* 2018 [PMID: 29334560 DOI: 10.1097/SLA.0000000000002668]

**P-Reviewer:** Mesa H **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

****

**Figure 1** **Arterial phase computed tomography scan.** A: a low-density round mass measuring about 1.5 cm × 1.1 cm in the pancreatic head; B: dilated pancreatic duct.

****

**Figure 2** **Pathological examination of the lesion in the pancreatic head.** A: Spindle cells with marked nuclear atypia and brisk mitotic activity arranged in a storiform or fascicular pattern (hematoxylin and eosin stain); B, C: Spindle cells exhibited strong diffuse positivity for cytokeratin 19 (B) and vimentin (C).

****

**Figure 3 Pathological examination of the metastatic lymph nodes.** A: Spindle cells with marked nuclear atypia and brisk mitotic activity arranged in a storiform or fascicular pattern (hematoxylin and eosin stain); B, C: Spindle cells exhibited strong diffuse positivity for cytokeratin 19 (B) and vimentin (C).